Study guide
3.8 Medical, Oncologic, and Treatment History Review
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
3.8 Medical, Oncologic, and Treatment History Review
Key Takeaways Explain This Topic AI
Medical and Treatment History is a named sub-topic (2B) worth 6 scored items on the CDR CSO content outline, tested as judgment about which chart data change the nutrition plan.
ECOG performance status runs 0 (fully active) to 5 (dead); ECOG 3-4 signals that a patient is bed- or chair-bound more than half of waking hours and shifts nutrition goals toward symptom control.
Altered GI anatomy predicts predictable deficiencies: total gastrectomy removes intrinsic factor (lifelong B12), pancreaticoduodenectomy causes exocrine insufficiency, and ileal resection over roughly 100 cm causes B12 and bile-salt malabsorption.
Chemotherapy nadir falls around days 7-14 of most cytotoxic cycles, so intake, weight, and symptom data must be interpreted against where the patient sits in the treatment cycle.
Medication reconciliation is part of the history: pemetrexed requires folic acid and B12 supplementation, metformin and long-term proton pump inhibitors deplete B12, and PPIs reduce absorption of several oral tyrosine kinase inhibitors.
Last updated: August 2026
3.8 Medical, Oncologic, and Treatment History Review
Quick Summary: CDR's content outline lists Medical and Treatment History (2B) as a distinct sub-topic worth 6 scored items — as many as Diagnostic and Laboratory Testing. Exam items in this area rarely ask you to recall a definition. They give you a chart and ask which piece of history changes the nutrition prescription: the resection performed, the drug in the regimen, the cumulative radiation dose, the performance status, or the day of the cycle.
Why the History Drives the Nutrition Diagnosis
Nutrition assessment in oncology is not a snapshot. A 6% weight loss means something entirely different in a patient two weeks after esophagectomy than in a patient on maintenance immunotherapy who has been weight-stable for a year. The history supplies the etiology half of every nutrition diagnosis you will write — and on the exam, the distractors are usually interventions that would be correct if the etiology were different.
Work the oncology chart in a fixed order so nothing is missed:
Pathology and staging record — tumour site, histology, grade, receptor or molecular markers, and the TNM stage group (T = primary tumour, N = regional nodes, M = distant metastasis; lymphomas use Ann Arbor instead). Note which staging edition the pathologist cited; stage groupings are revised between editions. Stage drives treatment intent, and treatment intent drives how aggressive nutrition support should be.
Treatment intent — curative , neoadjuvant (before surgery), adjuvant (after surgery), or palliative . Neoadjuvant therapy means a major operation is coming, so preserving lean mass now buys surgical tolerance later. Palliative intent means burden of the intervention is weighed differently.
The regimen itself — agent names, doses, schedule, and the number of cycles completed versus planned.
Cumulative exposures — total radiation dose and field, anthracycline lifetime dose, prior platinum exposure.
Surgical history — every resection, with what was removed.
Comorbidities and baseline — diabetes, chronic kidney disease, cirrhosis, inflammatory bowel disease, prior bariatric surgery, dysphagia, dentition.
Medication list , including over-the-counter products and herbals.
Treatment Timing: Where in the Cycle Is This Patient?
The single most common history error is assessing a patient without asking which day of the cycle it is .
Timepoint What you will see Assessment implication
Days 1-3 post-infusion Acute nausea, taste change, fatigue Intake is at its worst; do not set the baseline here
Days 7-14 (nadir) Neutrophil, platelet, haemoglobin low point Food-safety counselling, infection risk, fatigue-limited intake
Days 15-21 (recovery) Appetite and intake rebound The realistic window for repletion and oral supplement trials
Week 4-7 of chemoradiation Cumulative mucositis, enteritis, dermatitis Symptom burden is progressive, not cyclical — deterioration is expected, not a treatment failure
Radiation toxicity accumulates with dose rather than cycling, so a head and neck patient at 40 Gy will be worse at 60 Gy no matter what you do. That distinction — cyclical versus cumulative toxicity — is a favourite exam discriminator, because it determines whether you wait for recovery or escalate to tube feeding now.
Surgical History → Predictable Deficiency Map
Procedure Anatomy removed or bypassed Predictable nutrition consequence
Esophagectomy Distal oesophagus, gastric conduit, vagal trunks Delayed gastric emptying, early satiety, dumping, reflux when supine
Total gastrectomy Stomach and all parietal cells Loss of intrinsic factor → lifelong B12 replacement ; dumping; iron, calcium, and vitamin D malabsorption
Partial gastrectomy / Billroth Antrum and pylorus Dumping syndrome, rapid transit, iron deficiency
Pancreaticoduodenectomy (Whipple) Pancreatic head, duodenum, distal stomach Exocrine insufficiency requiring PERT, delayed gastric emptying, new-onset diabetes
Ileal resection >100 cm Terminal ileum B12 and bile-salt malabsorption, steatorrhoea, fat-soluble vitamin loss, oxalate kidney stones
- Total colectomy with end ileostomy Colon and rectum Large sodium and water losses; high-output stoma risk
- Neck dissection / laryngectomy Swallowing musculature, larynx Dysphagia, aspiration risk, altered airway
A single line in the operative history — "extended right hemicolectomy with 120 cm of terminal ileum resected" — should immediately generate a B12, fat-soluble vitamin, and oxalate plan without any laboratory prompt.
Performance Status: ECOG and Karnofsky
Performance status is a history variable, recorded by the oncologist, and it is the most portable predictor of nutrition benefit in the whole chart.
- ECOG Description Karnofsky (approx.)
- 0 Fully active, no restriction 100-90
- 1 Restricted in strenuous activity; ambulatory, light work possible 80-70
- 2 Ambulatory, all self-care, no work ; up >50% of waking hours 60-50
- 3 Limited self-care; confined to bed or chair >50% of waking hours 40-30
- 4 Completely disabled; totally confined to bed or chair 20-10
- 5 Dead 0
ECOG 0-2 generally supports active nutrition intervention including tube feeding when indicated. ECOG 3-4 combined with refractory cachexia and a life expectancy under three months is the classic exam signal to stop escalating and pivot to comfort-focused feeding. Karnofsky measures the same construct on a 100-to-0 scale in ten-point steps; know that ECOG 3 corresponds roughly to Karnofsky 40-30.
Medication Reconciliation as History
Agent Nutrition-relevant consequence
Pemetrexed Mandatory folic acid supplementation started before therapy plus intramuscular B12 to reduce haematologic and mucosal toxicity
- Cisplatin Renal magnesium and potassium wasting; hypomagnesaemia often outlasts treatment
- Vincristine Autonomic neuropathy → constipation and ileus
Irinotecan Early cholinergic diarrhoea (minutes to hours) versus late secretory diarrhoea (days) — different management
- Corticosteroids Hyperglycaemia, sodium retention, muscle catabolism, bone loss
- Opioids Constipation that will not resolve with fibre alone
- Metformin B12 depletion with long-term use
Proton pump inhibitors B12 and magnesium depletion; reduced absorption of pH-dependent oral tyrosine kinase inhibitors
Always ask separately about supplements and herbals — patients do not consider them medications, and they are the source of most clinically significant interactions on this exam.
Applying It: A Worked History
A 64-year-old woman is referred on day 9 of cycle 2 of adjuvant FOLFOX after a low anterior resection for stage III rectal cancer. She reports 4 kg loss since surgery, poor intake, and loose stools. Her chart shows type 2 diabetes on metformin for nine years and a completed course of neoadjuvant chemoradiation to the pelvis.
The history alone predicts the plan: day 9 places her at nadir , so today's intake is the trough rather than her steady state; prior pelvic radiation makes chronic radiation enteropathy — not simply chemotherapy diarrhoea — a live cause of the loose stools; nine years of metformin flags B12 assessment before you attribute her fatigue to anaemia of chronic disease; and oxaliplatin predicts cold-induced dysaesthesia, which means the room-temperature and cold-food strategies that help most nauseated patients are exactly wrong for her during the infusion week.